Luca Laurenti, MD

Section of Hematology, Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Italy

n/a

Poster(s):

• 1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.

• 1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.

• 1219 - The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.

• 1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.

• 1224 - Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.

• 2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study

• 2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT

• 2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?